Clinical trial
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor…
NCT00360763 · Huazhong University of Science and Technology, Other · Unknown status
Key facts
| NCT number | NCT00360763 |
|---|---|
| Title | Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody |
| Lead sponsor | Huazhong University of Science and Technology, Other |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | candesartan cilexetil |
| Enrollment | 600 |
| Completion | Dec 1, 2006 |
| First posted | Aug 7, 2006 |
| Last update posted | Aug 7, 2006 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: